Question 1

Which peptides are in the Wolverine stack?

Accepted Answer

Two of them, BPC-157 (body protection compound 157) and TB-500 (a synthetic fragment of thymosin beta-4). That is the version almost every seller means, and it is the version the one animal experiment tested. The reviews covering this field list the compounds separately and never as a stack. A 2026 primer for sports doctors reports that key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. A 2026 scoping review takes in 6 emerging peptides: BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu (copper peptide). Longer versions circulate under other names. GLOW adds GHK-Cu (copper tripeptide-1) to the same two compounds, and KLOW adds KPV on top of that. None of those names appears in a published paper either. Adding a compound adds a third separate literature rather than a third measured effect, which is the point most of these comparisons turn on.

Question 2

Is the composition of the Wolverine stack standardised?

Accepted Answer

No, and there is nothing it could be standardised against. Because no study among the research behind this page uses the name, there is no reference formulation, no agreed ratio and no defined course. The one experiment that gave both compounds fixed its own figures for its own purposes. It ran BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and treatments were administered intraperitoneally for four weeks, intraperitoneally meaning into the belly of the animal. That is a six-to-one split chosen for a rat with a freshly repaired tendon. Nor is there a settled figure for either compound taken by itself, since a 2026 scoping review of peptides marketed for recovery found the studies it read varied widely in how much was given and by which route. A ratio picked for groups of eight rats is an experimental setting rather than a formulation standard, and nothing among the research behind this page turns it into one.

Question 3

Has the pair ever been compared against each compound alone?

Accepted Answer

Once, in rats, and that comparison is the only one of its kind anywhere. In 2026, thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157, TB-500, and combined BPC-157 + TB-500 (BPC + TB). That is exactly the design a comparison needs. Each compound on its own, the two together, and an untreated group to measure all of them against. The result ran against the premise of stacking. Biomechanical testing revealed higher maximum load to failure values in the BPC-157 and TB-500 groups compared to controls, reaching statistical significance in the TB-500 group. The combined arm did not clear either single arm. The authors found no additive effect from combining the two, and suggest this may reflect convergence on shared downstream pathways. One experiment in thirty-two animals is a starting point rather than a settled answer, and it has not been replicated.

Question 4

What did that experiment actually measure?

Accepted Answer

Tendons, in a testing rig, four weeks after surgery. Maximum load to failure was assessed biomechanically, which means each repaired tendon was pulled until it tore and the force was written down. The tissue was then stained and read under a microscope, and expression of collagen types I and III was assessed immunohistochemically, meaning the two kinds of collagen were stained and counted. At four weeks, tendons were harvested for biomechanical testing or histological evaluation. Every number in the study required the tendon to come out of the animal first. So the only direct comparison of the pair against its parts sits at the level of a dissected rat tendon at four weeks. Its authors call the work exploratory and say both peptides warrant further investigation as candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies. None of those readings is something a person could watch happening rather than infer.

Question 5

Is there a human comparison of the pair against one compound?

Accepted Answer

Only an arithmetic one, inside a retrospective chart review at a single clinic. A retrospective study was done at the Institute for Hormonal Balance in Orlando, Florida, USA. Of the 16 patients, 12 had received only BPC 157 as an intra-articular injection, and 11 of the 12 patients (91.6%) had significant improvement in knee pain. The other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4, and of the patients who received both peptides, 75% showed significant improvement. Twelve people set beside four is a difference between two small groups rather than a comparison. There was no control arm, no randomisation and no blinding, and no specific tools were used to measure their improvement in function, quality of life, stiffness or activities of daily living. The review says as much in its own opening, that the use of peptides BPC157 and thymosin-beta-4 (TB4) has not been studied. That chart review is taken apart in more detail on the BPC-157 comparison page, which is where the two compounds are set against each other directly.

Question 6

How does the evidence behind each half compare?

Accepted Answer

They are unequal in opposite directions, which is the most useful thing a comparison can say here. BPC-157 has the deeper animal literature and almost no trials among the sources. A 2025 systematic review identified a total of 544 articles from 1993 to 2024, and after duplicates were removed, 36 studies were included (35 preclinical studies, 1 clinical study). A 2025 narrative review counts the human side at only three pilot studies have examined BPC-157 in humans. Thymosin beta 4 has the opposite shape, a long registry trail and little orthopaedic work. Completed entries include a Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers, a Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers, and a Study of Thymosin Beta 4 in Patients With Pressure Ulcers. A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds was terminated instead. So one half has been studied widely in rats and barely in people, and the other has been in people repeatedly, for conditions nobody buys it for.

Question 7

Do the thymosin beta 4 trials count as trials of TB-500?

Accepted Answer

Not directly, and this is the sharpest difference between the two halves of the stack. A 2026 review describes thymosin beta 4 as a highly conserved 43-amino-acid peptide encoded by the X-linked TMSB4x gene. TB-500 is a short piece cut out of that, which a 2026 primer records by writing TB-4 and its derivative TB-500. The registered trials listed above gave the protein, not the piece. One registry entry names the piece itself. It is titled TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD, it is recruiting, and it has not reported. A registration shows that somebody is asking a question rather than that an answer exists. A 43-amino-acid protein and the fragment named in that title for residues 17 to 23 are not the same molecule, so a human trial of the first is thin evidence about the second. For the stack it means one half has very little human evidence and the other half has human evidence about a near relative.

Question 8

What has each compound actually been studied for?

Accepted Answer

Two almost separate maps, touching at one rat tendon. BPC-157's work is gut and musculoskeletal. A 2018 review reports that only BPC 157 was consistently effective in all of the models of acute/chronic injury of esophagus, stomach, duodenum and lower gastrointestinal tract, and that BPC 157 - using same regimens like in gastrointestinal healing studies - improves tendon, ligament and bone healing. A 2021 review adds skin to the list, covering incisional/excisional wound, deep burns, diabetic ulcers, and alkali burns, all of it in rats. Thymosin beta 4's work went somewhere else entirely. A 2026 review evaluates its renoprotective efficacy across models of acute and chronic kidney injury. In mice, a 7-day rhTB4 treatment prevented cardiac dysfunction and fibrosis 28 days post-I/R surgery. A 2025 study ran it through brain tissue grown in a dish and then through animals, where the beneficial effects of Tβ4 were also revealed in 5xfAD model mice, a strain bred to develop Alzheimer-like changes. Stacking the two means stacking a tendon and gut literature on top of a cornea, heart and kidney one, which is a different proposition from stacking two effects on one tissue.

Question 9

How does the Wolverine stack compare with GLOW and KLOW?

Accepted Answer

They are the same idea with more compounds in the vial. GLOW adds GHK-Cu (copper tripeptide-1) to BPC-157 and TB-500, and KLOW adds KPV as well. The third compound brings its own gap. A 2026 primer for sports doctors reports that GHK-Cu showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use for musculoskeletal conditions. A 2026 orthopaedic review groups all three under one heading, where wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation. So a comparison between the two-compound and three-compound versions is a comparison between two untested mixtures. Neither has been given to a person in a published study, and the only combination experiment on record stopped at two compounds in rats. Adding a compound adds another separate literature and another set of unmeasured interactions rather than a measured gain. What is known about the three-compound version is gathered on the GLOW page.

Question 10

What else gets listed alongside these two compounds?

Accepted Answer

The reviews that cover BPC-157 and TB-500 cover a handful of others, and the contrast is worth a minute. A 2026 primer for sports doctors reports that key peptides evaluated included BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. One name on that list is an approved medicine and the rest are not. Tesamorelin, approved for treating HIV-associated lipodystrophy, a shift in where the body stores fat, has no supporting orthopaedic evidence. An approval for one use carries nothing at all into another use. A 2026 scoping review of the same ground adds a warning about a third name. Some peptides such as MK-677 were associated with significant risks including congestive heart failure. That is not one of the two in the stack, and the line is often quoted as though it were. The same review ends on the whole set, concluding that the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. Being filed next to a better known name is a choice made by the people writing the review. It is not a result, and it is the only sense in which this pair has been set against anything else.

Question 11

Is the Wolverine peptide stack good?

Accepted Answer

The word has nothing to attach to, because no study we could find has measured the pair in a person. Begin with the real signal, because there is one. In rats whose Achilles tendon had been cut through and repaired, biomechanical testing revealed higher maximum load to failure values in the BPC-157 and TB-500 groups compared to controls, reaching statistical significance in the TB-500 group. In the same rats, both BPC-157 and TB-500 were associated with improved histopathological parameters and extracellular matrix organization during early Achilles tendon repair. That is a genuine result in an animal, and it belongs to the single compounds. Then the part that bears on stacking. In the same experiment, the combined arm did not clear either single arm, and the authors report the absence of additive effects with combination therapy. The one time anybody set the pair against its parts, the pair was not ahead of them. A 2026 scoping review covering both compounds concludes that the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. A repaired rat tendon at four weeks and a human shoulder at four months are different questions, and only the first one has been asked.

Question 12

How do the two compare on approval and sporting status?

Accepted Answer

They compare closely, because neither half carries a licence anywhere that counts. The difference worth knowing sits on the doping side, where the paperwork has moved for one of them and not for the other. A 2025 patent review records that this compound was temporarily banned by the World Anti-Doping Agency (WADA) in 2022 (it is not currently listed as banned by the WADA), while two reviews published a year later still call it banned in sport. Among these sources nothing records a comparable reversal for the thymosin half, which a 2026 primer for sports doctors describes flatly: both remain banned substances in sports. Prohibited lists are set by each sporting body and revised on its own schedule, which is why two reviews a year apart can disagree about one compound. That is a difference in record-keeping rather than in standing, and the hub page carries the fuller account of where approval itself stands. The 2025 systematic review of BPC-157 in orthopaedic sports medicine draws the practical conclusion for both halves, recommending that clinicians counsel athletes to understand their organizations' rules to remain compliant with medication/supplement safety and testing standards. Neither half of the stack improves the position of the other half, because an unapproved compound added to an unapproved compound leaves both where they were.

Question 13

What would a real comparison of the Wolverine stack need?

Accepted Answer

The design already exists. It has only ever been run in animals. A comparison needs four arms: no compound, each compound on its own, and both together. That is what the 2026 rat experiment built, with eight rats in each group: control, BPC-157, TB-500, and combined BPC-157 + TB-500 (BPC + TB). Running the same shape in people would need a defined injury, a control arm and an endpoint that does not require taking the tissue out. The reviews name the missing pieces. A 2026 review of peptides in ageing lists optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy among its significant knowledge gaps. A 2026 primer for sports doctors adds that significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients. Until that work is done, a comparison between the Wolverine stack and its parts is a comparison between one animal result and two separate literatures rather than between two measured outcomes.

Group	Patients	Significant improvement in knee pain
BPC-157 alone, injected into the knee	12	11 of 12 (91.6%)
BPC-157 plus TB4	4	75%

Wolverine stack comparisons and stacks